Hyperpolarized 13C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC

Elisabeth Bliemsrieder, Georgios Kaissis, Martin Grashei, Geoffrey J. Topping, Jennifer Altomonte, Christian Hundshammer, Fabian Lohöfer, Irina Heid, Dominik Keim, Selamawit Gebrekidan, Marija Trajkovic‐Arsic, Alina M. Winkelkotte, Katja Steiger, Roman Nawroth, Jens T. Siveke, Markus Schwaiger, Marcus R. Makowski, Franz Schilling, Rickmer BrarenScientific 2021 · DOI

Abstract

The in vivo assessment of tissue metabolism represents a novel strategy for the evaluation of oncologic disease. Hepatocellular carcinoma (HCC) is a high-prevalence, high-mortality tumor entity often discovered at a late stage. Recent evidence indicates that survival differences depend on metabolic alterations in tumor tissue, with particular focus on glucose metabolism and lactate production. Here, we present an in vivo imaging technique for metabolic tumor phenotyping in rat models of HCC. Endogenous HCC was induced in Wistar rats by oral diethyl-nitrosamine administration. Peak lactate-to-alanine signal ratios (L/A) were assessed with hyperpolarized magnetic resonance spectroscopic imaging (HPMRSI) after [1-<sup>13</sup>C]pyruvate injection. Cell lines were derived from a subset of primary tumors, re-implanted in nude rats, and assessed in vivo with dynamic hyperpolarized magnetic resonance spectroscopy (HPMRS) after [1-<sup>13</sup>C]pyruvate injection and kinetic modelling of pyruvate metabolism, taking into account systemic lactate production and recirculation. For ex vivo validation, enzyme activity and metabolite concentrations were spectroscopically quantified in cell and tumor tissue extracts. Mean peak L/A was higher in endogenous HCC compared to non-tumorous tissue. Dynamic HPMRS revealed higher pyruvate-to-lactate conversion rates (k<sub>pl</sub>) and lactate signal in subcutaneous tumors derived from high L/A tumor cells, consistent with ex vivo measurements of higher lactate dehydrogenase (LDH) levels in these cells. In conclusion, HPMRS and HPMRSI reveal distinct tumor phenotypes corresponding to differences in glycolytic metabolism in HCC tumor tissue.

Introduction

Hepatocellular carcinoma (HCC) remains a significant clinical challenge due to its high prevalence, late-stage discovery, and high mortality rates. A critical factor in patient outcomes is the metabolic heterogeneity of the tumor tissue. Specifically, the "Warburg effect"—the preference of cancer cells for aerobic glycolysis and lactate production—is a hallmark of aggressive disease. Identifying these metabolic phenotypes in vivo could revolutionize personalized treatment, yet current methods are limited. Invasive biopsies carry high risks for patients with chronic liver disease, and standard $^{18}$F-FDG PET imaging is often confounded by the high baseline glucose consumption of healthy liver tissue.

Methods: Real-Time Metabolic Imaging

To overcome these limitations, this study utilizes Hyperpolarized $^{13}$C-pyruvate Magnetic Resonance Spectroscopic Imaging (HPMRSI). By "hyperpolarizing" $^{13}$C-labeled pyruvate, the magnetic resonance signal is enhanced by several orders of magnitude, enabling the real-time tracking of its enzymatic conversion into lactate and alanine within the living body.

The researchers employed two distinct rat models:

  1. Endogenous HCC: Induced via oral administration of diethyl-nitrosamine (DENA) to mimic natural tumor progression in the liver.
  2. Subcutaneous HCC: Derived from primary tumor cell lines (High Lactate, LA-H; and Low Lactate, LA-L) and re-implanted to study stable metabolic phenotypes.

A key methodological advancement was the development of a two-site kinetic exchange model. This model accounts for systemic lactate recirculation—lactate produced elsewhere in the body that flows into the tumor—ensuring that the calculated pyruvate-to-lactate conversion rate ($k_{pl}$) reflects local tumor metabolism rather than systemic noise.

In vivo metabolic imaging of endogenous HCC. (a) Anatomical MRI. (b-d) Metabolic maps for pyruvate, lactate, and alanine. (e) Comparison of lactate-to-alanine (L/A) ratios between control and tumor tissue.

Results and Metabolic Phenotyping

The study successfully demonstrated that HPMRSI can distinguish HCC from healthy liver tissue. In the endogenous model, tumors exhibited a significantly higher mean peak lactate-to-alanine (L/A) signal ratio ($1.60 \pm 0.50$) compared to healthy controls ($1.04 \pm 0.05$). This metabolic shift was clearly visible in the spatial maps, where lactate signals were concentrated within the tumor boundaries.

Furthermore, the metabolic profiles were found to be stable and heritable. Cell lines derived from high-lactate primary tumors (LA-H) maintained their aggressive, highly glycolytic phenotype when grown subcutaneously. These LA-H tumors not only showed higher $k_{pl}$ rates in vivo ($0.041 \pm 0.008$ s$^{-1}$) but also grew faster than their LA-L counterparts ($0.028 \pm 0.01$ s$^{-1}$).

Ex vivo spectroscopic analysis of tissue extracts confirmed these findings. Tumors showed significantly higher concentrations of lactate relative to alanine and increased activity of Lactate Dehydrogenase (LDH) relative to Glutamate Pyruvate Transaminase (GPT), the enzyme responsible for alanine production.

Ex vivo validation of metabolic phenotypes. (a) Concentration ratios of lactate to alanine (cL/cA). (b) Activity ratios of LDH to GPT. Both show significant elevation in tumor tissue compared to control.

Discussion and Future Directions

The ability to non-invasively phenotype HCC metabolism represents a major step toward precision oncology. By quantifying the flux through specific enzymatic pathways, clinicians could potentially monitor therapy response or select patients for metabolic-targeted treatments without the need for repeated biopsies.

However, technical hurdles remain. HPMRSI currently suffers from low spatial resolution and a very short signal window (30-40 seconds) due to the rapid decay of the hyperpolarized state. Future research will focus on improving signal-to-noise ratios and exploring other hyperpolarized substrates, such as $^{13}$C-glutamate or zymonic acid, to probe oxidative phosphorylation and tissue pH. These advancements could broaden the application of metabolic MRI to a wider range of oncologic and metabolic diseases.

Summary updated

Abstract

The in vivo assessment of tissue metabolism represents a novel strategy for the evaluation of oncologic disease. Hepatocellular carcinoma (HCC) is a high-prevalence, high-mortality tumor entity often discovered at a late stage. Recent evidence indicates that survival differences depend on metabolic alterations in tumor tissue, with particular focus on glucose metabolism and lactate production. Here, we present an in vivo imaging technique for metabolic tumor phenotyping in rat models of HCC. Endogenous HCC was induced in Wistar rats by oral diethyl-nitrosamine administration. Peak lactate-to-alanine signal ratios (L/A) were assessed with hyperpolarized magnetic resonance spectroscopic imaging (HPMRSI) after [1-<sup>13</sup>C]pyruvate injection. Cell lines were derived from a subset of primary tumors, re-implanted in nude rats, and assessed in vivo with dynamic hyperpolarized magnetic resonance spectroscopy (HPMRS) after [1-<sup>13</sup>C]pyruvate injection and kinetic modelling of pyruvate metabolism, taking into account systemic lactate production and recirculation. For ex vivo validation, enzyme activity and metabolite concentrations were spectroscopically quantified in cell and tumor tissue extracts. Mean peak L/A was higher in endogenous HCC compared to non-tumorous tissue. Dynamic HPMRS revealed higher pyruvate-to-lactate conversion rates (k<sub>pl</sub>) and lactate signal in subcutaneous tumors derived from high L/A tumor cells, consistent with ex vivo measurements of higher lactate dehydrogenase (LDH) levels in these cells. In conclusion, HPMRS and HPMRSI reveal distinct tumor phenotypes corresponding to differences in glycolytic metabolism in HCC tumor tissue.
BibTeX
@inproceedings{bliemsrieder2021hyperpolarized,
  author = {Elisabeth Bliemsrieder and Georgios Kaissis and Martin Grashei and Geoffrey J. Topping and Jennifer Altomonte and Christian Hundshammer and Fabian Lohöfer and Irina Heid and Dominik Keim and Selamawit Gebrekidan and Marija Trajkovic‐Arsic and Alina M. Winkelkotte and Katja Steiger and Roman Nawroth and Jens T. Siveke and Markus Schwaiger and Marcus R. Makowski and Franz Schilling and Rickmer Braren},
  title = {{Hyperpolarized 13C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC}},
  booktitle = {Scientific},
  year = {2021},
  doi = {10.1038/s41598-020-80952-4},
}
Figure